APOE ε4 and the cognitive genetics of multiple sclerosis

Neurology

Volumn 74, Issue 20, 2010, Pages 1611-1618

  Ghaffar, O ^a,b,e   Reis, M ^c,e   Pennell, N ^c   O'Connor, P ^d,e   Feinstein, A ^a,b,e  

^a Neuropsychiatry and Brain Sciences Programs   (Canada)

^b Departments of Psychiatry   (Canada)

^c SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^d ST MICHAEL'S HOSPITAL   (Canada)

^e UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E4;

ADULT; ADVERSE OUTCOME; ALLELE; ARTICLE; CASE CONTROL STUDY; CLINICAL ARTICLE; COGNITION; COGNITIVE DEFECT; COMPREHENSION; CONTROLLED STUDY; DISEASE COURSE; DISEASE DURATION; EDUCATIONAL STATUS; EMPLOYMENT STATUS; ETHNICITY; EVALUATION; EXPANDED DISABILITY STATUS SCALE; FEMALE; GENETIC ANALYSIS; HETEROZYGOTE; HUMAN; INTELLIGENCE QUOTIENT; MALE; MORBIDITY; MULTIPLE SCLEROSIS; PREDICTOR VARIABLE; PRIORITY JOURNAL; WALKING; ANALYSIS OF VARIANCE; CHI SQUARE DISTRIBUTION; GENETIC PREDISPOSITION; GENETICS; HOSPITALIZATION; MIDDLE AGED; NEUROPSYCHOLOGICAL TEST; PATIENT SELECTION;

ADULT; ALLELES; ANALYSIS OF VARIANCE; APOLIPOPROTEIN E4; CHI-SQUARE DISTRIBUTION; COGNITION DISORDERS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; NEUROPSYCHOLOGICAL TESTS; PATIENT SELECTION; SEVERITY OF ILLNESS INDEX;

EID: 77952478035     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e3181e074a7     Document Type: Article

References (37)

1. Rao SM, Leo GJ, Bernardin L, Unverzagt F. Cognitive dysfunction in multiple sclerosis: I: frequency, patterns, and prediction. Neurology 1991;41:685-691.
2. Rao SM, Leo GJ, Ellington L, Nauertz T, Bernardin L, Unverzagt F. Cognitive dysfunction in multiple sclerosis: II: impact on employment and social functioning. Neurology 1991;41:692-696.
3. Mitchell AJ, Benito-Leon J, Gonzalez JM, Rivera-Navarro J. Quality of life and its assessment in multiple sclerosis: integrating physical and psychological components of well-being. Lancet Neurol 2005;4:556-566.
4. Feinstein A. The Clinical Neuropsychiatry of Multiple Sclerosis, 2nd ed. Cambridge: Cambridge University Press; 2007.
5. Chiaravalloti ND, DeLuca J. Cognitive impairment in multiple sclerosis. Lancet Neurol 2008;7:1139-1151.
6. Burwick RM, Ramsay PP, Haines JL, et al. APOE epsilon variation in multiple sclerosis susceptibility and disease severity: Some answers. Neurology 2006;66:1373-1383.
7. Bertram L, McQueen MB, Mullin K, Blacker D, Tanzi RE. Systematic meta-analyses of Alzheimer disease genetic association studies: The AlzGene database. Nat Genet 2007;39:17-23.
8. Oliveri RL, Cittadella R, Sibilia G, et al. APOE and risk of cognitive impairment in multiple sclerosis. Acta Neurol Scand 1999;100:290-295.
9. Savettieri G, Messina D, Andreoli V, et al. Gender-related effect of clinical and genetic variables on the cognitive impairment in multiple sclerosis. J Neurol 2004;251:1208-1214.
10. Parmenter BA, Denney DR, Lynch SG, Middleton LS, Harlan LM. Cognitive impairment in patients with multiple sclerosis: association with the APOE gene and promoter polymorphisms. Mult Scler 2007;13:25-32.
11. Koutsis G, Panas M, Giogkaraki E, et al. APOE epsilon4 is associated with impaired verbal learning in patients with MS. Neurology 2007;68:546-549.
12. Shi J, Zhao CB, Vollmer TL, Tyry TM, Kuniyoshi SM. APOE epsilon 4 allele is associated with cognitive impairment in patients with multiple sclerosis. Neurology 2008; 70:185-190.
13. van der Walt A, Stankovich J, Bahlo M, et al. Apolipopro-tein genotype does not influence MS severity, cognition, or brain atrophy. Neurology 2009;73:1018-1025.
14. Bookheimer S, Burggren A. APOE-4 genotype and neuro-physiological vulnerability to Alzheimer's and cognitive aging. Annu Rev Clin Psychol 2009;5:343-362.
15. Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald criteria." Ann Neurol 2005;58:840-846.
16. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444-1452.
17. Cutter GR, Baier ML, Rudick RA, et al. Development of a multiple sclerosis functional composite as a clinical trial outcome measure. Brain 1999;122(Pt 5):871-882.
18. Grober E, Sliwinski M. Development and validation of a model for estimating premorbid verbal intelligence in the elderly. J Clin Exp Neuropsychol 1991;13:933-949.
19. Beck AT, Steer RA, Brown GK. Beck Depression Inventory (BDI)-II Manual. San Antonio: The Psychological Corporation; 1996.
20. Benedict RH, Fischer JS, Archibald CJ, et al. Minimal neuropsychological assessment of patients with MS: A consensus approach. Clin Neuropsychol 2002;16:381-397.
21. Benedict RH, Cookfair D, Gavett R, et al. Validity of the minimal assessment of cognitive function in multiple sclerosis (MACFIMS). J Int Neuropsychol Soc 2006;12:549-558.
22. Nilsson LG, Nyberg L, Backman L. Genetic variation in memory functioning. Neurosci Biobehav Rev 2002;26: 841-848.
23. Kantarci OH, Hebrink DD, Achenbach SJ, et al. Association of APOE polymorphisms with disease severity in MS is limited to women. Neurology 2004;62:811-814.
24. Faul F, Erdfelder E, Lang AG, Buchner A. G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods 2007;39:175-191.
25. Corder EH, Saunders AM, Risch NJ, et al. Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. Nat Genet 1994;7:180-184.
26. Utermann G, Langenbeck U, Beisiegel U, Weber W. Genetics of the apolipoprotein E system in man. Am J Hum Genet 1980;32:339-347.
27. Prakash RS, Snook EM, Lewis JM, Motl RW, Kramer AF. Cognitive impairments in relapsing-remitting multiple sclerosis: a meta-analysis. Mult Scler 2008;14:1250-1261.
28. Houston WS, Delis DC, Lansing A, et al. Executive function asymmetry in older adults genetically at-risk for Alzheimer's disease: verbal versus design fluency. J Int Neuropsychol Soc 2005;11:863-870.
29. Finton MJ, Lucas JA, Rippeth JD, et al. Cognitive asymmetries associated with apolipoprotein E genotype in patients with Alzheimer's disease. J Int Neuropsychol Soc 2003;9:751-759.
30. Pa J, Boxer A, Chao LL, et al. Clinical-neuroimaging characteristics of dysexecutive mild cognitive impairment. Ann Neurol 2009;65:414-423.
31. Small BJ, Rosnick CB, Fratiglioni L, Backman L. Apoli-poprotein E and cognitive performance: a meta-analysis. Psychol Aging 2004;19:592-600.
32. Strober L, Englert J, Munschauer F, Weinstock-Guttman B, Rao S, Benedict R. Sensitivity of conventional memory tests in multiple sclerosis: comparing the rao brief repeat-able neuropsychological battery and the minimal assessment of cognitive function in MS. Mult Scler 2009;15: 1077-1084.
33. Carlesimo GA, Caltagirone C, Gainotti G. The mental deterioration battery: normative data, diagnostic reliability and qualitative analyses of cognitive impairment: the Group for the Standardization of the Mental Deterioration Battery. Eur Neurol 1996;36:378-384.
34. Benedict R. Standards for sample composition and impairment classification in neuropsychological studies of multiple sclerosis. Mult Scler 2009;15:777-778.
35. Bishop EG, Dickson AL, Allen MT. Psychometric intelligence and performance on selective reminding. Clin Neu-ropsychol 1990;4:141-150.
36. Sawcer S. The complex genetics of multiple sclerosis: pitfalls and prospects. Brain 2008;131:3118-3131.
37. Sadovnick AD, Jacobs DH. MS and cognition and APOE: the ongoing conundrum about biomarkers. Neurology 2008;70:164-165.